<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37612772</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Clinical characteristics and prognosis in systemic lupus erythematosus-associated pulmonary arterial hypertension based on consensus clustering and risk prediction model.</ArticleTitle><Pagination><StartPage>155</StartPage><MedlinePgn>155</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">155</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-023-03139-y</ELocationID><Abstract><AbstractText Label="BACKGROUND">Pulmonary arterial hypertension (PAH) is a severe complication of systemic lupus erythematosus (SLE). This study aims to explore the clinical characteristics and prognosis in SLE-PAH based on consensus clustering and risk prediction model.</AbstractText><AbstractText Label="METHODS">A total of 205 PAH (including 163 SLE-PAH and 42 idiopathic PAH) patients were enrolled retrospectively based on medical records at the First Affiliated Hospital of Zhengzhou University from July 2014 to June 2021. Unsupervised consensus clustering was used to identify SLE-PAH subtypes that best represent the data pattern. The Kaplan-Meier survival was analyzed in different subtypes. Besides, the least absolute shrinkage and selection operator combined with Cox proportional hazards regression model were performed to construct the SLE-PAH risk prediction model.</AbstractText><AbstractText Label="RESULTS">Clustering analysis defined two subtypes, cluster 1 (n&#x2009;=&#x2009;134) and cluster 2 (n&#x2009;=&#x2009;29). Compared with cluster 1, SLE-PAH patients in cluster 2 had less favorable levels of poor cardiac, kidney, and coagulation function markers, with higher SLE disease activity, less frequency of PAH medications, and lower survival rate within 2&#xa0;years (86.2% vs. 92.8%) (P&#x2009;&lt;&#x2009;0.05). The risk prediction model was also constructed, including older age at diagnosis (&#x2265;&#x2009;38&#xa0;years), anti-dsDNA antibody, neuropsychiatric lupus, and platelet distribution width (PDW).</AbstractText><AbstractText Label="CONCLUSIONS">Consensus clustering identified two distinct SLE-PAH subtypes which were associated with survival outcomes. Four prognostic factors for death were discovered to construct the SLE-PAH risk prediction model.</AbstractText><CopyrightInformation>&#xa9; 2023. BioMed Central Ltd., part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Mengmeng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Chunyi</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Chaoying</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Congcong</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Runzhi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Menghui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Zhaohui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Zhaohui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. fcczhengzh@zzu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081029" MajorTopicYN="Y">Pulmonary Arterial Hypertension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Consensus clustering</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">Pulmonary arterial hypertension</Keyword><Keyword MajorTopicYN="N">Risk prediction model</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>24</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>23</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37612772</ArticleId><ArticleId IdType="pmc">PMC10463535</ArticleId><ArticleId IdType="doi">10.1186/s13075-023-03139-y</ArticleId><ArticleId IdType="pii">10.1186/s13075-023-03139-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fei Y, Shi X, Gan F, Li X, Zhang W, Li M, et al. Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years. Clin Rheumatol. 2014;33(1):57&#x2013;63. doi: 10.1007/s10067-013-2383-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-013-2383-3</ArticleId><ArticleId IdType="pubmed">24046218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cansu DU, Korkmaz C. Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis,&#xa0; and treatment. Clin Rheumatol. 2022;41. 10.1007/s10067-022-06446-y.</Citation><ArticleIdList><ArticleId IdType="pubmed">36396789</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu L, Hao Y, Fan Y, Huang H, Yang X, Xie A, et al. Mortality and prognostic factors in Chinese patients with systemic lupus erythematosus. Lupus. 2018;27(10):1742&#x2013;1752. doi: 10.1177/0961203318789788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318789788</ArticleId><ArticleId IdType="pubmed">30060721</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, et al. Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Eur Respir J. 2019;53(2):1800081.</Citation><ArticleIdList><ArticleId IdType="pubmed">30635295</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J, Wang Y, Huang C, Yang X, Zhao J, Wang Q, et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a PRISMA-compliant systematic review and meta-analysis. Autoimmun Rev. 2016;15(3):250&#x2013;257. doi: 10.1016/j.autrev.2015.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.11.012</ArticleId><ArticleId IdType="pubmed">26640159</ArticleId></ArticleIdList></Reference><Reference><Citation>Parperis K, Velidakis N, Khattab E, Gkougkoudi E, Kadoglou N. Systemic Lupus Erythematosus and Pulmonary Hypertension. Int J Mol Sci. 2023;24(6):5085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10049584</ArticleId><ArticleId IdType="pubmed">36982160</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu J, Li M, Wang Y, Duan X, Luo H, Zhao C, et al. Predicting the risk of pulmonary arterial hypertension in systemic lupus erythematosus: a Chinese systemic lupus erythematosus treatment and research group cohort study. Arthritis Rheumatol. 2021;73(10):1847&#x2013;1855. doi: 10.1002/art.41740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41740</ArticleId><ArticleId IdType="pubmed">34105259</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Zhao JL, Ding F, Yang J, Wang J, Zeng XF, et al. Recommendations for the diagnosis and treatment of connective tissue disease associated pulmonary arterial hypertension in China. Zhonghua Nei Ke Za Zhi. 2022;61(11):1206&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">36323561</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SL, Chen YT, Lee YC, Carns M, Aren K, Korman B, et al. Differences in symptom experience among patients with systemic sclerosis: a cluster analytic approach to identifying subgroups. Rheumatology (Oxford). 2023;62(SI):SI64-SI73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9910572</ArticleId><ArticleId IdType="pubmed">35920770</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama T, Furuta S, Hiraguri M, Ikeda K, Inaba Y, Kagami SI, et al. Latent class analysis of 216 patients with adult-onset Still's disease. Arthritis Res Ther. 2022;24(1):7. doi: 10.1186/s13075-021-02708-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02708-3</ArticleId><ArticleId IdType="pmc">PMC8722082</ArticleId><ArticleId IdType="pubmed">34980244</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun F, Lei Y, Wu W, Guo L, Wang K, Chen Z, et al. Two distinct clinical phenotypes of pulmonary arterial hypertension secondary to systemic lupus erythematosus. Ann Rheum Dis. 2019;78(1):148&#x2013;150. doi: 10.1136/annrheumdis-2018-214197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214197</ArticleId><ArticleId IdType="pubmed">30232194</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez MZ, Comin CH, Casanova D, Bruno OM, Amancio DR, Costa L, et al. Clustering algorithms: a comparative approach. PLoS ONE. 2019;14(1):e0210236. doi: 10.1371/journal.pone.0210236.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0210236</ArticleId><ArticleId IdType="pmc">PMC6333366</ArticleId><ArticleId IdType="pubmed">30645617</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria D, Garibaldi JM, Ambrogi F, Green AR, Powe D, Rakha E, et al. A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med. 2010;40(3):318&#x2013;330. doi: 10.1016/j.compbiomed.2010.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2010.01.003</ArticleId><ArticleId IdType="pubmed">20106472</ArticleId></ArticleIdList></Reference><Reference><Citation>Thongprayoon C, Vaitla P, Jadlowiec CC, Leeaphorn N, Mao SA, Mao MA, et al. Use of machine learning consensus clustering to identify distinct subtypes of Black kidney transplant recipients and associated outcomes. JAMA Surg. 2022;157(7):e221286. doi: 10.1001/jamasurg.2022.1286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamasurg.2022.1286</ArticleId><ArticleId IdType="pmc">PMC9069346</ArticleId><ArticleId IdType="pubmed">35507356</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z, Waikar SS, Schmidt IM, Landis JR, Hsu CY, Shafi T, et al. Subtyping CKD patients by consensus clustering: the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Soc Nephrol. 2021;32(3):639&#x2013;653. doi: 10.1681/ASN.2020030239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020030239</ArticleId><ArticleId IdType="pmc">PMC7920178</ArticleId><ArticleId IdType="pubmed">33462081</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger R, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618&#x2013;3731. doi: 10.1093/eurheartj/ehac237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac237</ArticleId><ArticleId IdType="pubmed">36017548</ArticleId></ArticleIdList></Reference><Reference><Citation>Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, et al. Development and validation of an abridged version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7462639</ArticleId><ArticleId IdType="pubmed">32882243</ArticleId></ArticleIdList></Reference><Reference><Citation>Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141(2):354&#x2013;362. doi: 10.1378/chest.11-0676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.11-0676</ArticleId><ArticleId IdType="pubmed">21680644</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Qian J, Li M, Zhang X, Wei W, Zuo X, et al. Risk assessment in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Ther Adv Chronic Dis. 2022;13:20406223221112528. doi: 10.1177/20406223221112528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221112528</ArticleId><ArticleId IdType="pmc">PMC9310292</ArticleId><ArticleId IdType="pubmed">35898921</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide MV, Aguirre C. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev. 2013;12(3):410&#x2013;415. doi: 10.1016/j.autrev.2012.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2012.07.010</ArticleId><ArticleId IdType="pubmed">22841984</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma Z, Urowitz MB, Gladman DD. Systemic lupus erythematosus disease activity index 2000 responder index-50 website. J Rheumatol. 2013;40(5):733. doi: 10.3899/jrheum.130030.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.130030</ArticleId><ArticleId IdType="pubmed">23637378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572&#x2013;1573. doi: 10.1093/bioinformatics/btq170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btq170</ArticleId><ArticleId IdType="pmc">PMC2881355</ArticleId><ArticleId IdType="pubmed">20427518</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1&#x2013;22. doi: 10.18637/jss.v033.i01.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v033.i01</ArticleId><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Li M, Qian J, Wang Q, Zhao J, Yang Z, et al. Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: baseline characteristics and risk factors. Int J Rheum Dis. 2019;22(5):921&#x2013;928. doi: 10.1111/1756-185X.13478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.13478</ArticleId><ArticleId IdType="pubmed">30746850</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J, Li M, Zhao J, Wang Q, Tian Z, Zeng X. Inflammation in SLE-PAH: good news or not? Ann Rheum Dis. 2019;78(12):e135. doi: 10.1136/annrheumdis-2018-214605.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214605</ArticleId><ArticleId IdType="pubmed">30429120</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JS, Kim D, Joo YB, Won S, Lee J, Shin J, et al. Factors associated with development and mortality of pulmonary hypertension in systemic lupus erythematosus patients. Lupus. 2018;27(11):1769&#x2013;1777. doi: 10.1177/0961203318788163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318788163</ArticleId><ArticleId IdType="pubmed">30028258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wang Y, Li X, Huang Y, Sun X, Wang Q, et al. Serum uric acid is associated with disease severity and may predict clinical outcome in patients of pulmonary arterial hypertension secondary to connective tissue disease in Chinese: a single-center retrospective study. BMC Pulm Med. 2020;20(1):272. doi: 10.1186/s12890-020-01309-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12890-020-01309-1</ArticleId><ArticleId IdType="pmc">PMC7574226</ArticleId><ArticleId IdType="pubmed">33076877</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow SL, Chandran V, Fazelzad R, Johnson SR. Prognostic factors for survival in systemic lupus erythematosus associated pulmonary hypertension. Lupus. 2012;21(4):353&#x2013;364. doi: 10.1177/0961203311429815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311429815</ArticleId><ArticleId IdType="pubmed">22127457</ArticleId></ArticleIdList></Reference><Reference><Citation>Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L, et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int. 2011;31(2):183&#x2013;189. doi: 10.1007/s00296-009-1255-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-009-1255-2</ArticleId><ArticleId IdType="pubmed">20012052</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro-Checa C, Kumar S, Ramiro S, Beaart-van DVL, Eikenboom J, Ronen I, et al. Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort. Lupus. 2019;28(1):94&#x2013;103. doi: 10.1177/0961203318816819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318816819</ArticleId><ArticleId IdType="pmc">PMC6304692</ArticleId><ArticleId IdType="pubmed">30526327</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Li M, Liu Y, Wang Q, Guo X, Zhao J, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. Medicine (Baltimore) 2016;95(10):e2761. doi: 10.1097/MD.0000000000002761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000002761</ArticleId><ArticleId IdType="pmc">PMC4998855</ArticleId><ArticleId IdType="pubmed">26962774</ArticleId></ArticleIdList></Reference><Reference><Citation>Prete M, Fatone MC, Vacca A, Racanelli V, Perosa F. Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature. Clin Exp Rheumatol. 2014;32(2):267&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">24351505</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia YK, Tu SH, Hu YH, Wang Y, Chen Z, Day HT, et al. Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese population. Rheumatol Int. 2013;33(5):1211&#x2013;1217. doi: 10.1007/s00296-012-2525-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-012-2525-y</ArticleId><ArticleId IdType="pmc">PMC3632720</ArticleId><ArticleId IdType="pubmed">22983159</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabu A, Patel K, Yee CS, Nightingale P, Situnayake RD, Thickett DR, et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) 2009;48(12):1506&#x2013;1511. doi: 10.1093/rheumatology/kep203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kep203</ArticleId><ArticleId IdType="pubmed">19671698</ArticleId></ArticleIdList></Reference><Reference><Citation>Tselios K, Gladman DD, Urowitz MB. Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. Open Access Rheumatol. 2017;9:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5191623</ArticleId><ArticleId IdType="pubmed">28053559</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronwall C, Akhter E, Oh C, Burlingame RW, Petri M, Silverman GJ. IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol. 2012;142(3):390&#x2013;398. doi: 10.1016/j.clim.2012.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2012.01.002</ArticleId><ArticleId IdType="pmc">PMC3632049</ArticleId><ArticleId IdType="pubmed">22297166</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng YG, Yang T, Xiong CM, He JG, Liu ZH, Gu Q, et al. Platelet distribution width and mean platelet volume in idiopathic pulmonary arterial hypertension. Heart Lung Circ. 2015;24(6):566&#x2013;572. doi: 10.1016/j.hlc.2014.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2014.11.025</ArticleId><ArticleId IdType="pubmed">25573235</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SY, Du J, Lu XN, Xu JH. Platelet distribution width as a novel indicator of disease activity in systemic lupus erythematosus. J Res Med Sci. 2018;23:48. doi: 10.4103/jrms.JRMS_1038_16.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/jrms.JRMS_1038_16</ArticleId><ArticleId IdType="pmc">PMC5996572</ArticleId><ArticleId IdType="pubmed">29937910</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Yu Y, Hu S. Platelet distribution width level in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension and its diagnostic value. Arch Rheumatol. 2020;35(3):394&#x2013;400. doi: 10.46497/ArchRheumatol.2020.7791.</Citation><ArticleIdList><ArticleId IdType="doi">10.46497/ArchRheumatol.2020.7791</ArticleId><ArticleId IdType="pmc">PMC7788649</ArticleId><ArticleId IdType="pubmed">33458663</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevuk U, Bahadir MV, Altindag R, Baysal E, Yaylak B, Ay N, et al. Value of serial platelet indices measurements for the prediction of pulmonary embolism in patients with deep venous thrombosis. Ther Clin Risk Manag. 2015;11:1243&#x2013;1249. doi: 10.2147/TCRM.S89355.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S89355</ArticleId><ArticleId IdType="pmc">PMC4548763</ArticleId><ArticleId IdType="pubmed">26316769</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinholt PJ, Hvas AM, Nybo M. An overview of platelet indices and methods for evaluating platelet function in thrombocytopenic patients. Eur J Haematol. 2014;92(5):367&#x2013;376. doi: 10.1111/ejh.12262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.12262</ArticleId><ArticleId IdType="pubmed">24400878</ArticleId></ArticleIdList></Reference><Reference><Citation>Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol. 2012;8(9):534&#x2013;542. doi: 10.1038/nrrheum.2012.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2012.118</ArticleId><ArticleId IdType="pubmed">22868927</ArticleId></ArticleIdList></Reference><Reference><Citation>Habets KL, Huizinga TW, Toes RE. Platelets and autoimmunity. Eur J Clin Invest. 2013;43(7):746&#x2013;757. doi: 10.1111/eci.12101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.12101</ArticleId><ArticleId IdType="pubmed">23617819</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>